163 related articles for article (PubMed ID: 38574701)
21. Development and functional analysis of an anticancer T-cell medicine with immune checkpoint inhibitory ability.
Fujiwara K; Shigematsu K; Tachibana M; Okada N
IUBMB Life; 2020 Aug; 72(8):1649-1658. PubMed ID: 32255257
[TBL] [Abstract][Full Text] [Related]
22. Targeting CD28, CTLA-4 and PD-L1 costimulation differentially controls immune synapses and function of human regulatory and conventional T-cells.
Dilek N; Poirier N; Hulin P; Coulon F; Mary C; Ville S; Vie H; Clémenceau B; Blancho G; Vanhove B
PLoS One; 2013; 8(12):e83139. PubMed ID: 24376655
[TBL] [Abstract][Full Text] [Related]
23. Immune Checkpoint Blockade in Cancer Immunotherapy: Mechanisms, Clinical Outcomes, and Safety Profiles of PD-1/PD-L1 Inhibitors.
Yan Y; Zhang L; Zuo Y; Qian H; Liu C
Arch Immunol Ther Exp (Warsz); 2020 Nov; 68(6):36. PubMed ID: 33185750
[TBL] [Abstract][Full Text] [Related]
24. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors.
Duraiswamy J; Kaluza KM; Freeman GJ; Coukos G
Cancer Res; 2013 Jun; 73(12):3591-603. PubMed ID: 23633484
[TBL] [Abstract][Full Text] [Related]
25. Indirect Impact of PD-1/PD-L1 Blockade on a Murine Model of NK Cell Exhaustion.
Alvarez M; Simonetta F; Baker J; Morrison AR; Wenokur AS; Pierini A; Berraondo P; Negrin RS
Front Immunol; 2020; 11():7. PubMed ID: 32117218
[TBL] [Abstract][Full Text] [Related]
26. The role of PD-1/PD-L1 axis and macrophage in the progression and treatment of cancer.
Cai J; Qi Q; Qian X; Han J; Zhu X; Zhang Q; Xia R
J Cancer Res Clin Oncol; 2019 Jun; 145(6):1377-1385. PubMed ID: 30963235
[TBL] [Abstract][Full Text] [Related]
27. Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy.
Ren D; Hua Y; Yu B; Ye X; He Z; Li C; Wang J; Mo Y; Wei X; Chen Y; Zhou Y; Liao Q; Wang H; Xiang B; Zhou M; Li X; Li G; Li Y; Zeng Z; Xiong W
Mol Cancer; 2020 Jan; 19(1):19. PubMed ID: 32000802
[TBL] [Abstract][Full Text] [Related]
28. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
29. The implications of clinical risk factors, CAR index, and compositional changes of immune cells on hyperprogressive disease in non-small cell lung cancer patients receiving immunotherapy.
Kim SR; Chun SH; Kim JR; Kim SY; Seo JY; Jung CK; Gil BM; Kim JO; Ko YH; Woo IS; Shim BY; Hong SH; Kang JH
BMC Cancer; 2021 Jan; 21(1):19. PubMed ID: 33402127
[TBL] [Abstract][Full Text] [Related]
30. Mechanisms of primary and acquired resistance to PD-1/PD-L1 blockade and the emerging role of gut microbiome.
Zou R; Wang Y; Ye F; Zhang X; Wang M; Cui S
Clin Transl Oncol; 2021 Nov; 23(11):2237-2252. PubMed ID: 34002348
[TBL] [Abstract][Full Text] [Related]
31. Blocking of the PD-1/PD-L1 interaction by a novel cyclic peptide inhibitor for cancer immunotherapy.
Zhai W; Zhou X; Zhai M; Li W; Ran Y; Sun Y; Du J; Zhao W; Xing L; Qi Y; Gao Y
Sci China Life Sci; 2021 Apr; 64(4):548-562. PubMed ID: 32737851
[TBL] [Abstract][Full Text] [Related]
32. Hyperprogressive Disease (HPD) in Solid Tumours Receiving Immune Checkpoint Inhibitors in a Real-World Setting.
Kanjanapan Y; Guduguntla G; Varikara AK; Szajer J; Yip D; Cockburn J; Fadia M
Technol Cancer Res Treat; 2023; 22():15330338231209129. PubMed ID: 37885403
[No Abstract] [Full Text] [Related]
33. Immune-Checkpoint Blockade Therapy in Lymphoma.
Kuzume A; Chi S; Yamauchi N; Minami Y
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32751706
[TBL] [Abstract][Full Text] [Related]
34. Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation.
Wu M; Huang Q; Xie Y; Wu X; Ma H; Zhang Y; Xia Y
J Hematol Oncol; 2022 Mar; 15(1):24. PubMed ID: 35279217
[TBL] [Abstract][Full Text] [Related]
35. Hyper-Progressive Disease: The Potential Role and Consequences of T-Regulatory Cells Foiling Anti-PD-1 Cancer Immunotherapy.
Tay C; Qian Y; Sakaguchi S
Cancers (Basel); 2020 Dec; 13(1):. PubMed ID: 33375291
[TBL] [Abstract][Full Text] [Related]
36. Nanoscale Reduced Graphene Oxide-Mediated Photothermal Therapy Together with IDO Inhibition and PD-L1 Blockade Synergistically Promote Antitumor Immunity.
Yan M; Liu Y; Zhu X; Wang X; Liu L; Sun H; Wang C; Kong D; Ma G
ACS Appl Mater Interfaces; 2019 Jan; 11(2):1876-1885. PubMed ID: 30582788
[TBL] [Abstract][Full Text] [Related]
37. Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker.
Wang Z; Wu X
Cancer Med; 2020 Nov; 9(21):8086-8121. PubMed ID: 32875727
[TBL] [Abstract][Full Text] [Related]
38. Treg-mediated acquired resistance to immune checkpoint inhibitors.
Saleh R; Elkord E
Cancer Lett; 2019 Aug; 457():168-179. PubMed ID: 31078738
[TBL] [Abstract][Full Text] [Related]
39. PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy.
Dermani FK; Samadi P; Rahmani G; Kohlan AK; Najafi R
J Cell Physiol; 2019 Feb; 234(2):1313-1325. PubMed ID: 30191996
[TBL] [Abstract][Full Text] [Related]
40. Advance investigation on synthetic small-molecule inhibitors targeting PD-1/PD-L1 signaling pathway.
Awadasseid A; Wu Y; Zhang W
Life Sci; 2021 Oct; 282():119813. PubMed ID: 34256042
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]